Objective-To establish whether immunoscintigraphy with antibody to myosin may detect acute myocardial infarction without electrocardiographic changes.
Introduction
The diagnosis of acute myocardial infarction is based on typical chest pain, evolving electrocardiographic changes, and increased concentrations ofserum cardiac enzymes. Patients commonly present, however, with chest pain and a small increase in cardiac enzyme concentrations but with no electrocardiographic changes of acute myocardial infarction. Several noncardiac conditions may also produce a small increase in cardiac enzyme concentrations, even in the MB isoenzyme of creatine kinase.' This observation has lent impetus to the development of a new imaging technique that may be used to detect and localise necrotic myocardium. Experimental studies have shown that antibody against the cardiac contractile protein myosin binds specifically to the myocardial cells if there is irreversible injury to the cell membrane. When the antibody is labelled with a radioactive isotope a standard gammacamera can be used to localise experimental' and human myocardial infarctions2; this technique has a high sensitivity and specificity.
We describe the use of myosin antibody labelled with indium-111 as a diagnostic tool (fig 2) , and the rest all had a single region of uptake involving one or more contiguous walls of the left ventricle. The myocardial infarction in these seven patients was further confirmed by the presence of a localised perfusion abnormality in six and regional wall motion abnormalities in all.
No adverse effects were observed in any patient after administration of labelled myosin antibody, and the blood samples obtained two weeks and six weeks after its injection showed no antibody response.
Results
Of the 119 patients who had imaging, 75 had acute myocardial infarction, 17 Tc-pyrophosphate has been used as a "hot spot" imaging agent for acute myocardial infarction, but the technique is marred by appreciable extracardiac uptake and non-specific uptake by ischaemic (as opposed to necrotic) myocardium." 12 On the other hand, the specificity of antibodies to myosin for necrotic myocardium has been firmly established in experimental studies.4 In a necroscopic study, when a patient died suddenly after acute myocardial infarction and cardiac rupture after having received "'In labelled antibody 12 hours before death, the sites of uptake of tracer were closely correlated with histologically outlined areas of myocardial necrosis.'3 Of course, this technique is not specific for acute myocardial infarction alone. Any other condition producing myocardial necrosis (for example, viral myocarditis or transplant rejection) would also result in uptake of the labelled antibody by the heart.'4'5 But the pattern is entirely different in these conditions, producing a picture of generalised uptake quite unlike that observed in acute infarction.
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